Posted by JohnX2 on April 12, 2002, at 22:55:05
In reply to Neurotrophic med to be released, posted by Anna Laura on April 11, 2002, at 23:38:34
Hi AnnaLaura,This company Neotherapeutics seems exciting and i was wondering what other ventures they are into.
Regards,
John
> http://www.neotherapeutics.com/pr/r020409.html
>
> April 9, 2002
>
> Company Press Release
>
> NeoTherapeutics Issued Patent for Neotrofin(TM) and its Analogues' Ability to Reduce
> Oxidative Stress
>
> IRVINE, Calif., April 9 /PRNewswire-FirstCall/-- NeoTherapeutics, Inc. (Nasdaq: NEOT) announced today that the Company has been issued U.S. Patent No. 6,350,752 B1 entitled ``Carbon Monoxide Dependent Guanylyl Cyclase Modifiers and Methods of Use.'' The new patent is one of a family of patents on purine derivatives and covers the use of Neotrofin and related compounds to treat certain conditions relating to oxidative stress. To date, in the United States, NeoTherapeutics has been issued 9 patents and 17 patent applications are pending at this time. Additional foreign patents corresponding to the U.S. patents and patents pending have been issued or are pending at this time.
>
> This patent expands the intellectual property protection of NeoTherapeutics' original patented technology platform of compounds, which includes Neotrofin(TM) and AIT-034, to certain diseases that involve oxidative stress. Oxidative stress has been implicated in Alzheimer's disease, Parkinson's disease and several other diseases and conditions. NeoTherapeutics expects to report results from a pivotal clinical study of Neotrofin in patients with Alzheimer's disease by mid-May 2002. Phase 2 studies of Neotrofin are underway in Parkinson's disease, spinal cord injury and chemotherapy-induced neuropathy.
>
> ``This is the second patent that has been issued this year, and with 17 patent applications pending and additional filings being processed, we expect to continue expanding the intellectual property base underlying Neotrofin and the other drugs in our pipeline,'' stated Michelle S. Glasky, Ph.D., Vice President, Scientific Affairs of NeoTherapeutics.
>
> NeoTherapeutics seeks to create value for stockholders through the discovery and development of central nervous system (CNS) drugs, in-licensing and commercialization of anti-cancer drugs, and the licensing out of new drug targets discovered through genomics research. The Company has two drugs addressing major medical needs in pivotal/phase 3 stage of development: Neotrofin(TM) for Alzheimer's disease and satraplatin for prostate cancer. Additional neurology and anti-cancer drugs such are in phase 1 and 2 human clinical trials and the Company has a rich pipeline of pre-clinical drug candidates. For additional information visit the Company's web site at www.neot.com.
>
> This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
>
>
>
> Contacts:
> MEDIA RELATIONS
> Jon Siegal
> Ronald Trahan Associates (RTA) Inc.
> (508) 647-9782, ext. 15
>
> INVESTOR RELATIONS
> John McManus
> NeoTherapeutics, Inc.
poster:JohnX2
thread:102832
URL: http://www.dr-bob.org/babble/20020408/msgs/102918.html